{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-230984","form_type":"8-K","ticker":"PHAT","cik":"0001783183","company_name":"Phathom Pharmaceuticals, Inc.","filed_at":"2025-10-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.440220+00:00","generated_at":"2026-05-17T04:36:36.883436+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Phathom Pharmaceuticals appoints Sanjeev Narula as CFO and Business Officer effective Oct 6, 2025","bullets":["Sanjeev Narula named Chief Financial and Business Officer; replaces Robert Breedlove as principal financial officer.","Initial base salary of $550,000 with annual target bonus of 50% of base salary.","Receives stock options for 200,000 shares (4-year vest) and 144,000 RSUs (3-year annual vest).","Narula previously CFO of Intra-Cellular Therapies and Viatris; brings extensive biopharma finance experience.","Robert Breedlove continues as Vice President, Finance and principal accounting officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-230984","json":"https://secwatch.observer/filing/0001193125-25-230984.json","markdown":"https://secwatch.observer/filing/0001193125-25-230984.md","text":"https://secwatch.observer/filing/0001193125-25-230984.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783183/000119312525230984/0001193125-25-230984-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783183/000119312525230984/d76139d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:36:36.883436+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}